Next, we estimated the fraction of observed de novo mutations that contribute to OCD risk, based on our dataset. By dividing the de novo mutation rate difference between cases and controls by the rate in cases, we estimate that 49.2% (CI 3.4–95.0%) of de novo LGD and 29.5% (CI 6.0–53.0%) of de novo Mis-D mutations contribute to OCD risk. As a group, we estimate that 33.9% (CI 13.3–54.6%) of damaging (LGD + Mis-D) de novo mutations contribute to OCD risk (Figure 2B).